Published on 22/10/2021 3:52:00 PM | Source: Angel One Ltd
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel https://t.me/InvestmentGuruIndia
Download Telegram App before Joining the Channel
Below is quote on Biocon Q2FY22 number below expectation, stock down 6% by Mr. Yash Gupta, Equity Research Analyst, Angel One Ltd
Biocon Limited reported revenue from operation at 1840 crores up by 5%, YoY 1750 crores in Q2FY21, Biosimilars has done well for the company up by 10% at ₹743 crores while generics down by 12% at ₹530 crores. The company reported an EBITDA of ₹551 crores up by 35% YoY on the back of better profit margins and product mix. The company reported a net profit of ₹138 crores down by 18% as compared to ₹169 crores in Q2FY21 as the company reported an exceptional loss of ₹50 Crores.
Numbers are below the market expectation biosimilars and research services have done well for the company but generic was down more than 12%.
Above views are of the author and not of the website kindly read disclaimer
Instant Expert View: India's second-quarter GDP growth slows to 6.3% on higher prices
World stocks upbeat on hopes for China re-opening, inflation peaking
Logitech launches new webcams, headphones in India
India v New Zealand, 3rd ODI: Felt that we bowled a bit on the shorter side, says Shikhar Dhawan
